Otsuka has announced the launch of its new Meptin Swinghaler procaterol hydrochloride DPI for the treatment of asthma and COPD in Japan as of July 2, 2014. The Meptin Swinghaler was approved in Japan in February 2014. According to the company, Japan has over 1 million asthma patients, and Meptin’s share of the Japanese market is over 50%.
The Swinghaler, co-developed by Otsuka Pharmaceutical and Otsuka Techno Corporation, replaces the Meptin Clickhaler, which has been marketed since 2005. Otsuka markets various dosage forms of Meptin in a dozen countries.
Read the Otsuka press release.
